Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 14/20 | 0.85 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.85 |
| ▸ | PPARG | P37231 | 6/20 | 0.49 |
| ▸ | PPARA | Q07869 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Schweinfurthin B SCHEMBL12042782 | 1.00 | OSBP (0.85) | OSBPOSBP2PPARGPPARA | |
| Schweinfurthin E SCHEMBL24867154 | 0.93 | OSBP (0.77) | OSBPOSBP2 | |
| Schweinfurthin A SCHEMBL20003740 | 0.92 | OSBP (1.00) | OSBPOSBP2PPARGPPARA | |
| Schweinfurthin A SCHEMBL847068 | 0.92 | OSBP (1.00) | OSBPOSBP2PPARGPPARA | |
| Schweinfurthin A SCHEMBL29378071 | 0.92 | OSBP (1.00) | OSBPOSBP2PPARGPPARA | |
| SCHEMBL2608676 | 0.90 | OSBP (0.73) | OSBPOSBP2 | |
| SCHEMBL31547371 | 0.89 | OSBP (0.67) | OSBPOSBP2PPARGPPARA | |
| SCHEMBL12845798 | 0.89 | OSBP (0.67) | OSBPOSBP2PPARGPPARA | |
| 3-Deoxyschweinfurthin B SCHEMBL10043035 | 0.88 | OSBP (0.86) | OSBPOSBP2PPARGPPARA | |
| SCHEMBL17399632 | 0.87 | OSBP (0.64) | OSBPOSBP2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200405688-A1 | METHODS AND MATERIALS FOR TREATING CANCER | THE PENN STATE RESEARCH FOUNDATION | 2020-12-31 | — | — | US | claimed |
| WO-2019157502-A1 | METHODS AND MATERIALS FOR TREATING CANCER | THE PENN STATE RESEARCH FOUNDATION (US) | 2019-08-15 | — | — | WO | claimed |
| EP-3375441-A1 | SCHWEINFURTHINS AND USES THEREOF | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2018-09-19 | — | — | EP | claimed |
| EP-2432466-B1 | SCHWEINFURTHINS AND USES THEREOF | US HEALTH (US) | 2018-03-28 | — | — | EP | claimed |
| US-20120095089-A1 | SCHWEINFURTHINS AND USES THEREOF | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2012-04-19 | — | — | US | claimed |
| EP-2432466-A1 | SCHWEINFURTHINS AND USES THEREOF | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2012-03-28 | — | — | EP | claimed |
| WO-2010127235-A1 | SCHWEINFURTHINS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-04 | — | — | WO | claimed |
| US-12427133-B2 | Combination therapies comprising schweinfurthin compounds for treating cancer | THE PENN STATE RESEARCH FOUNDATION (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-20200405688-A1 | METHODS AND MATERIALS FOR TREATING CANCER | THE PENN STATE RESEARCH FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| WO-2019157502-A1 | METHODS AND MATERIALS FOR TREATING CANCER | THE PENN STATE RESEARCH FOUNDATION (US) | 2019-08-15 | — | — | WO | disclosed |
| EP-3375441-A1 | SCHWEINFURTHINS AND USES THEREOF | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-2432466-B1 | SCHWEINFURTHINS AND USES THEREOF | US HEALTH (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2010068877-A2 | COMPOUNDS THAT BIND OXYSTEROL BINDING PROTEINS, AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2009158516-A1 | SCHWEINFURTHIN ANALOGUES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20080227852-A1 | SCHWEINFURTHIN ANALOGUES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA | 2008-09-18 | — | — | US | disclosed |
| US-7358377-B2 | such as: 3-Deoxyschweinfurthin B; tested and were found to have anti-cancer by NCI 60-cell line anticancer assay; e.g. breast cancer or a cancer of the CNS or renal system | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2008-04-15 | — | — | US | disclosed |
| US-20080015232-A1 | SCHWEINFURTHIN ANALOGUES | US GOVERNMENT - SECRETARY FOR THE ARMY | 2008-01-17 | — | — | US | disclosed |
| EP-1732915-A2 | SCHWEINFURTHIN ANALOGUES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092878-A2 | SCHWEINFURTHIN ANALOGUES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427133-B2 | Combination therapies comprising schweinfurthin compounds for treating cancer | CD274, PDCD1, PDCD1LG2 | OSBP 3812/4885OSBP2 4071/4885PPARG 490/4885 |
| US-20200405688-A1 | METHODS AND MATERIALS FOR TREATING CANCER | CD274, PDCD1, MSH2 | OSBP 3404/4885OSBP2 3683/4885PPARG 1056/4885 |
| US-20120095089-A1 | SCHWEINFURTHINS AND USES THEREOF | VHL, WFS1, UPF1 | OSBP 4011/4885OSBP2 3204/4885PPARG 3980/4885 |
| US-20080015232-A1 | SCHWEINFURTHIN ANALOGUES | ERH, HRAS, HNRNPH1 | OSBP 2083/4885OSBP2 2163/4885PPARG 1653/4885 |
| US-20080227852-A1 | SCHWEINFURTHIN ANALOGUES | ERH, HRAS, HNRNPH1 | OSBP 2083/4885OSBP2 2163/4885PPARG 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.